Airsonett is an evidence-based, non-pharmaceutical treatment for atopic asthma. The treatment is non-invasive and has an excellent safety record.
Airsonett is most suitable for patients with the following clinical profile:
Poorly controlled (ACT<18) atopic asthma despite high treatment intensity (GINA 4) Hypersensitivity to at least one perennial allergen
ACT= Asthma Control Test
GINA= Global INitiative for Asthma
Relevant links for more facts and information about Airsonett